• Corbus reported positive topline results from its CANYON-1 Phase 1b trial of oral obesity drug CRB-913.
• The trial showed clinically meaningful weight loss across doses with continued improvement through the treatment period.
• Safety looked broadly comparable to marketed GLP-1 obesity drugs on psychiatric events, with an emerging gastrointestinal profile that appeared more tolerable.
• Full data will be presented as a late-breaking session at ObesityWeek 2026 in November.
• Plans include FDA discussions, a Phase 2 monotherapy study in the first half of 2027, and evaluation of combination use with GLP-1 therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140700PRIMZONEFULLFEED9825877) on September 14, 2026, and is solely responsible for the information contained therein.